<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209827">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356057</url>
  </required_header>
  <id_info>
    <org_study_id>G040150</org_study_id>
    <nct_id>NCT00356057</nct_id>
  </id_info>
  <brief_title>Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace</brief_title>
  <acronym>AVAIL</acronym>
  <official_title>AVAIL CLS/CRT: AV-node Ablation With CLS and CRT Pacing Therapies for the Treatment of AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of biventricular
      pacing over conventional right ventricular pacing in patients with persistent or permanent,
      symptomatic atrial fibrillation undergoing atrioventricular (AV) node ablation and permanent
      pacing therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, prospective, randomized, blinded trial. The study will consist
      of approximately 265 patients who require treatment of persistent or permanent, symptomatic
      atrial fibrillation by atrioventricular (AV) node ablation and permanent pacing therapy i.e.
      &quot;Ablate and Pace&quot; therapy. All patients enrolled into the clinical study will be randomly
      assigned to one of three groups using a randomization ratio of 2:2:1. Patients will be
      assigned to receive either biventricular (biV) pacing with CLS-based rate adaptive pacing
      using the legally marketed Protos DR/CLS (Group 1), or biventricular pacing with
      accelerometer-based rate adaptive pacing using the Stratos LV (Group 2), or right
      ventricular (RV) pacing with accelerometer-based rate adaptive pacing using the Stratos LV
      (Group 3). Patients in all three groups will be implanted with legally marketed right and
      left ventricular pacing leads. The patients, the core lab used to interpret the
      echocardiographic data and the Clinical Events Committee adjudicating crossover, patient
      death and congestive heart failure (CHF) hospitalizations will be blinded to the
      randomization assignment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment.
  </why_stopped>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Percentage Improvement From Baseline of the 6-minute Walk Test Distance and Minnesota Living With Heart Failure Quality of Life Score at 6-months</measure>
    <time_frame>Change from baseline to six months post-procedure</time_frame>
    <description>Combined, average percentage improvement in 6-minute walk test distance and Minnessota Living With Heart Failure Quality of Life score from baseline to 6-month follow-up for the Protos DR/CLS (Group 1) and Stratos LV (Group 2) compared with the active control (Group 3). The 6-minute walk test is a test that measure how far a patient can walk in 6 minutes in a standardized walking course. Percent Change (0% (worst)-100% (best))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>System-related Complication-free Rate</measure>
    <time_frame>at six months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in 6-minute Walk Test</measure>
    <time_frame>at six months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in QOL Score</measure>
    <time_frame>at six months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling Assessments by Echocardiography</measure>
    <time_frame>at six months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA Classification</measure>
    <time_frame>at six months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CHF Hospitalizations and Total Mortality</measure>
    <time_frame>at six months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Protos DR/CLS and Stratos LV CRT pacemakers</intervention_name>
    <description>Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Protos DR/CLS dual chamber pacemaker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the indications for therapy

          -  Persistent, symptomatic AF with poorly controlled rapid ventricular rates or
             permanent, symptomatic AF with poorly controlled rapid ventricular rates.

          -  Eligible for AV nodal ablation and permanent pacemaker implantation

          -  NYHA Class II or III heart failure

          -  Age â‰¥ 18 years

          -  Understand the nature of the procedure

          -  Ability to tolerate the surgical procedure required for implantation

          -  Give informed consent

          -  Able to complete all testing required by the clinical protocol

          -  Available for follow-up visits on a regular basis at the investigational site

        Exclusion Criteria:

          -  Meet one or more of the contraindications

          -  Have a life expectancy of less than six months

          -  Expected to receive heart transplantation within six months

          -  Enrolled in another cardiovascular or pharmacological clinical investigation

          -  Patients with an ICD, or being considered for an ICD

          -  Patients with previously implanted biventricular pacing systems

          -  Patients with previously implanted single or dual chamber pacing system with &gt; 50%
             documented ventricular pacing

          -  Patients with previous AV node ablation

          -  Six-minute walk test distance greater than 450 meters

          -  Any condition preventing the patient from being able to perform required testing

          -  Presence of another life-threatening, underlying illness separate from their cardiac
             disorder

          -  Conditions that prohibit placement of any of the lead systems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Orlov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Caritas Elizabeth, Boston, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Memorial</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Heart Foundation</name>
      <address>
        <city>LaPeer</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lone Star Arrhythmia</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 2, 2012</lastchanged_date>
  <firstreceived_date>July 21, 2006</firstreceived_date>
  <firstreceived_results_date>December 2, 2008</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>AV node ablation</keyword>
  <keyword>pacemaker</keyword>
  <keyword>congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 153 patients were enrolled at 22 clinical sites from December 9, 2004 (the first implant of the study) through May 12, 2008.</recruitment_details>
      <pre_assignment_details>No patients were excluded before assigment to groups. A total of 27 patients did not receive a device implant due to withdrawal of consent, inelegibility after randomization and unability to implant the LV lead.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>biV-pacing With CLS Rate Adaption (Protos CLS)</title>
          <description>Patients are implanted with a Protos CLS device, using the atrial port of the device for the left ventricular lead and the ventricular port for the ventricular lead to provide biV pacing. CLS is activated for rate adaptation.</description>
        </group>
        <group group_id="P2">
          <title>biV Pacing With Accelerometer Based Rate Adaption (Stratos LV)</title>
          <description>Patients are implanted with a Stratos LV device, with the atrial port plugged and the left ventricular port for the left ventricular lead and the right ventricular port for the right ventricular lead to provide biV pacing. The acceleromer is activated for rate adaptation.</description>
        </group>
        <group group_id="P3">
          <title>RV Pacing With Accelerometer Based Rate Adaption (Stratos LV)</title>
          <description>Patients are implanted with a Stratos LV device, with the atrial port plugged and the left ventricular port for the left ventricular lead and the right ventricular port for the right ventricular lead to provide biV pacing. The device is programmed to right ventricular pacing only. The acceleromer is activated for rate adaptation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>IMPLANTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>biV-pacing With CLS Rate Adaption (Protos CLS)</title>
          <description>Patients are implanted with a Protos CLS device, using the atrial port of the device for the left ventricular lead and the ventricular port for the ventricular lead to provide biV pacing. CLS is activated for rate adaptation.</description>
        </group>
        <group group_id="B2">
          <title>biV Pacing With Accelerometer Based Rate Adaption (Stratos LV)</title>
          <description>Patients are implanted with a Stratos LV device, with the atrial port plugged and the left ventricular port for the left ventricular lead and the right ventricular port for the right ventricular lead to provide biV pacing. The acceleromer is activated for rate adaptation.</description>
        </group>
        <group group_id="B3">
          <title>RV Pacing With Accelerometer Based Rate Adaption (Stratos LV)</title>
          <description>Patients are implanted with a Stratos LV device, with the atrial port plugged and the left ventricular port for the left ventricular lead and the right ventricular port for the right ventricular lead to provide biV pacing. The device is programmed to right ventricular pacing only. The acceleromer is activated for rate adaptation.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.1" spread="8.4"/>
                    <measurement group_id="B2" value="72.7" spread="7.8"/>
                    <measurement group_id="B3" value="72.3" spread="8.2"/>
                    <measurement group_id="B4" value="73.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Percentage Improvement From Baseline of the 6-minute Walk Test Distance and Minnesota Living With Heart Failure Quality of Life Score at 6-months</title>
        <description>Combined, average percentage improvement in 6-minute walk test distance and Minnessota Living With Heart Failure Quality of Life score from baseline to 6-month follow-up for the Protos DR/CLS (Group 1) and Stratos LV (Group 2) compared with the active control (Group 3). The 6-minute walk test is a test that measure how far a patient can walk in 6 minutes in a standardized walking course. Percent Change (0% (worst)-100% (best))</description>
        <time_frame>Change from baseline to six months post-procedure</time_frame>
        <population>Patients included in this analysis are those patients with complete six minute walk test and Quality of Life data at both baseline and the six-month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>biV-pacing With CLS Rate Adaption (Protos CLS)</title>
            <description>Patients are implanted with a Protos CLS device, using the atrial port of the device for the left ventricular lead and the ventricular port for the ventricular lead to provide biV pacing. CLS is activated for rate adaptation.</description>
          </group>
          <group group_id="O2">
            <title>biV Pacing With Accelerometer Based Rate Adaption (Stratos LV)</title>
            <description>Patients are implanted with a Stratos LV device, with the atrial port plugged and the left ventricular port for the left ventricular lead and the right ventricular port for the right ventricular lead to provide biV pacing. The acceleromer is activated for rate adaptation.</description>
          </group>
          <group group_id="O3">
            <title>RV Pacing With Accelerometer Based Rate Adaption (Stratos LV)</title>
            <description>Patients are implanted with a Stratos LV device, with the atrial port plugged and the left ventricular port for the left ventricular lead and the right ventricular port for the right ventricular lead to provide biV pacing. The device is programmed to right ventricular pacing only. The acceleromer is activated for rate adaptation.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percentage Improvement From Baseline of the 6-minute Walk Test Distance and Minnesota Living With Heart Failure Quality of Life Score at 6-months</title>
          <description>Combined, average percentage improvement in 6-minute walk test distance and Minnessota Living With Heart Failure Quality of Life score from baseline to 6-month follow-up for the Protos DR/CLS (Group 1) and Stratos LV (Group 2) compared with the active control (Group 3). The 6-minute walk test is a test that measure how far a patient can walk in 6 minutes in a standardized walking course. Percent Change (0% (worst)-100% (best))</description>
          <population>Patients included in this analysis are those patients with complete six minute walk test and Quality of Life data at both baseline and the six-month follow-up.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="5.7"/>
                    <measurement group_id="O2" value="42.5" spread="8.9"/>
                    <measurement group_id="O3" value="31.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>System-related Complication-free Rate</title>
        <time_frame>at six months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in 6-minute Walk Test</title>
        <time_frame>at six months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in QOL Score</title>
        <time_frame>at six months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Remodeling Assessments by Echocardiography</title>
        <time_frame>at six months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in NYHA Classification</title>
        <time_frame>at six months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of CHF Hospitalizations and Total Mortality</title>
        <time_frame>at six months post-procedure</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study duration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Groups</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Device related</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>LV lead related</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Other medical</sub_title>
                <counts group_id="E1" events="65" subjects_affected="45" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Procedure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>RV-lead related</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>LV lead related</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>RV lead related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Device related</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Procedure</sub_title>
                <counts group_id="E1" events="53" subjects_affected="48" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Other medical</sub_title>
                <counts group_id="E1" events="90" subjects_affected="55" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due lack of enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Katerina de Metz, Director Clinical Studies</name_or_title>
      <organization>BIOTRONIK, Inc.</organization>
      <phone>5036752169</phone>
      <email>katerina.demetz@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
